ArticleFrontiers in genetics2026
Reduced IQGAP2 promotes esophageal squamous cell carcinoma by regulating MEK/ERK MAPK pathway.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: IQ motif-containing GTPase activating protein 2 (IQGAP2) has been identified as a tumor suppressor in various cancers; however, its role in esophageal squamous cell carcinoma (ESCC) remains unclear. Methods: We analyzed IQGAP2 expression in tumor tissues from 236 ESCC patients using RNA sequencing and validated the findings with qPCR. EC9706 ESCC cell lines with IQGAP2 overexpression and knockdown were established via lentiviral transfection and selection. Cell proliferation was assessed using the CCK-8 assay, and activation of the MEK/ERK MAPK pathway was evaluated by Western blotting. Results: IQGAP2 expression was significantly decreased in tumor samples from ESCC patients. Overexpression of IQGAP2 markedly inhibited proliferation of ES9706 cells, whereas knockdown of IQGAP2 promoted cell proliferation. Mechanistically, decreased IQGAP2 expression enhances ESCC cell proliferation by activating the MEK/ERK MAPK signaling pathway. Conclusion: Our findings highlight IQGAP2 as a potential therapeutic target in ESCC, warranting further investigation for the development of effective treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.